Next-gen T cell player TCR2 Therapeutics sets stage for $100M-plus IPO as MPM's Baeuerle caps prolific year
Patrick Baeuerle has been busy. Right after steering next-gen BiTE company Harpoon Therapeutics toward an IPO, the MPM partner and immunologist is shepherding another oncology company with preclinical assets — TCR2 Therapeutics — into a public listing. And this time the biotech is looking for $100 million-plus in a market that’s been on a wild roller coaster ride.
The immunotherapy company is developing next-gen T-cell drugs for cancer in an effort to confront limitations posed by current T-cell and CAR-T therapies in solid tumors.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.